ISAtx-247 (Isotechnika/Roche)

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 542-550

  Dumont, Francis J ^a  

^a Medor Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; ISATX247;

ANIMAL; ARTHRITIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CALCINEURIN; CLINICAL TRIALS; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PSORIASIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3342914815     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. 195813 Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis. Witkamp L, Zonneveld IM, Jung EG, Schopf RE, Christophers E, Grossman R, Meffert H, Belaich S, Mahrle G, Van Joost T BR J DERMATOL 1995 133 1 95-103
2. 282683 Cyclosporin A and tacrolimus (FK-506). Immunosuppression through immunophilin-dependent inhibition of calcineurin function. Dumont FJ PRINCIPLES DRUG DEV TRANSPLANT AUTOIMMUN 1996 1 175-205
3. 285453 Discovery of less nephrotoxic FK-506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Brandt JA, Kawai M, Wagner R, Hsieh GC, Luly JR J PHARMACOL EXP THER 1997 283 3 1509-1519
4. 388807 Isotechnika Inc announces the development of ISAtx247 for the treatment of rheumatoid arthritis. Isotechnika Inc PRESS RELEASE 2000 November 07
5. 395645 Isotechnika Inc announces successful completion of phase I clinical trials for its new immunosuppressive drug ISAtx247. Isotechnika Inc PRESS RELEASE 2001 January 09
6. 396944 Isotechnika Inc announces development of its new immunosupressive drug ISAtx247 in treatment of psoriasis. Isotechnika Inc PRESS RELEASE 2001 January 25
7. 398373 New Drug for Prevention of Insulin-Dependent Diabetes. Isotechnika Inc PRESS RELEASE 2001 February 08
8. 413607 Preclinical efficacy of a novel calcineurin inhibitor: ISAtx247. Abel MD, Aspeslet LJ, Freitag DG, Halloran PF, Kneteman NM, Naicker SS, Trepanier DJ, Foster RT, Yatscoff RW AM J TRANSPLANTATION 2001 1 1 Abs 1191
9. 413608 ISAtx247: A novel calcineurin inhibitor with minimal renal toxicity. Abel MD, Aspeslet LJ, Freitag DJ, Halloran PF, Kneteman NT, Naicker SS, Trepanier DJ, Foster RT, Yatscoff RW AM J TRANSPLANTATION 2001 1 1 Abs 1192
10. 413613 Ex vivo evaluation of the immunosuppressive effect of the novel calcineurin inhibitor ISAtx247 on whole blood lymphocytes of non-human primates. Bisran T, Dambrin C, Villanueva JC, Yatscoff RW, Morris RE AM J TRANSPLANTATION 2001 1 1 Abs 1199
11. 413803 Phase 1 evaluation of a novel calcineurin inhibitor ISAtx247. Abel MD, Aspeslet LJ, Freitag DG, Halloran PF, Kneteman NM, Naicker S, Trepanier DJ, Foster RT, Yatscoff RW AM J TRANSPLANTATION 2001 1 1 Abs 1319
12. 414183 Isotechnika involved in $25 million special warrant financing. Isotechnika Inc PRESS RELEASE 2001 June 29
13. 417848 New drug tested in organ transplant patients - Isotechnika replaces Cyclosporine with ISAtx247 in phase II human trials. Isotechnika Inc PRESS RELEASE 2001 August 02
14. 420623 Isotechnika Inc announces second quarter 2001 financial results quarter highlighted by significant growth in diagnostic product sales, FDA and Health Canada approval to commence phase II human trials and signing of bought underwriting deal. Isotechnika Inc PRESS RELEASE 2001 August 29
15. 422279 Prevention and treatment of antigen-induced arthritis by ISAtx247, a novel calcineurin inhibitor. Maksymowych WP, Aspeslet L, Abel M, Trepanier D, Naicker R J RHEUMATOL 2001 28 Suppl 63 92
16. 422284 Amelioration of established collagen-induced arthritis by ISAtx247, a novel calcineurin inhibitor. Maksymowych WP, Aspeslet L, Abel M, Trepanier D, Naicker R J RHEUMATOL 2001 28 Suppl 63 93
17. 422287 A novel calcineurin inhibitor with minimal renal toxicity: ISAtx247. Yatscoff RW, Abel M, Aspeslet L, Freitag DG, Naicker R J RHEUMATOL 2001 28 Suppl 63 109
18. 424142 Isotechnika begins psoriasis trials. Isotechnika Inc PRESS RELEASE 2001 October 03
19. 440188 A tacrolimus-related immunosuppressant with reduced toxicity. Dumont FJ, Koprak S, Staruch MJ, Talento A, Koo G, Dasilva C, Sinclair PJ, Wong F, Woods J, Barker J, Pivnichny J et al TRANSPLANTATION 1998 65 1 18-26
20. 446732 Isotechnika and Roche sign largest drug development agreement in Canadian history. Isotechnika Inc PRESS RELEASE 2002 April 09
21. 446734 Roche strengthens its presence in transplantation medicine by signing agreement to co-develop Isotechnika's new drug. Hoffmann-La Roche Inc PRESS RELEASE 2002 April 09
22. 449607 Presentations to investors - Roche R&D Day for investors, Munich/Penzberg, Germany. Roche Holding AG COMPANY PRESENTATION 2002 April 25-26
23. 449687 United States Federal Trade Commission approves global drug development agreement signed by Isotechnika and Roche. Isotechnika Inc PRESS RELEASE 2002 April 29
24. 450789 Isotechnika and Roche to focus development of ISAtx247 in transplantation. Isotechnika Inc/Roche PRESS RELEASE 2002 May 10
25. 454091 ISAtx247: A novel calcineurin inhibitor. Aspeslet L, Freitag D, Trepanier D, Abel M, Naicker S, Kneteman N, Foster R, Yatscoff R TRANSPLANT PROC 2001 33 1-2 1048-1051
26. 465238 Isotechnika earns significant drug development milestone payment. Isotechnika Inc PRESS RELEASE 2002 September 26
27. 465840 Isotechnika and Roche announce completion of patient recruitment for ISA247 phase IIa clinical trial in kidney transplantation. Isotechnika Inc/Roche PRESS RELEASE 2002 October 03
28. 481300 Isotechnika's phase II clinical trial of ISA247 in patients with psoriasis yields impressive results. Isotechnika Inc PRESS RELEASE 2003 March 10
29. 489872 Isotechnika earns $21,900,000 CDN drug development milestone payment. Isotechnika Inc PRESS RELEASE 2003 May 15
30. 492349 Isotechnika releases final results of phase IIa kidney transplant trial at American Transplant Congress. Isotechnika Inc PRESS RELEASE 2003 June 04
31. 509752 Roche Holding AG - product pipeline. Roche Holding AG COMPANY WORLD WIDE WEB SITE 2003 October 16 http://www.roche.com
32. 515386 Development of the novel immunosuppressive agent ISAtx247 using a pharmacodynamic approach. Freitag G, Abel D, Aspeslet J, Trepanier J, Mayo R, Halloran PF, Kneteman NT, Morris RE, Gregory CR, Foster RT TOXICOL SCI 2003 72 1 Suppl 4
33. 515398 Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISAtx247. Maksymowych WP, Jhangri GS, Aspeslet L, Abel MD, Trepanier DJ, Naicker S, Freitag DG, Cooper BL, Foster RT, Yatscoff RW J RHEUMATOL 2002 29 8 1646-1652
34. 515401 Amelioration of established collagen-induced arthritis by ISAtx247, a novel calcineurin inhibitor. Maksymowych WP, Jhangri G, Aspeslet L, Abel M, Trepanier D, Naicker R, Freitag D, Foster R, Yatscoff RW ARTHRITIS RHEUM 2001 44 9 Suppl S367
35. 523826 Isotechnika Inc - FDA agrees to manufacturing plans for ISA247. Isotechnika Inc PRESS RELEASE 2004 February 19
36. 524578 FDA agrees to clinical development plans for ISA-247. Isotechnika Inc PRESS RELEASE 2004 February 25
37. 526549 The mechanism of action of cyclosporin A and FK-506. Schreiber SL, Crabtree GR IMMUNOL TODAY 1992 13 4 136-142
38. 2+/calcineurin signalling in cells of the immune system. Feske S, Okamura H, Hogan PG, Rao A BIOCHEM BIOPHYS RES COMMUN 2003 311 4 1117-1132
39. 526552 Cyclosporine nephrotoxicity. Burdmann EA, Andoh TF, Yu L, Bennett WM SEMIN NEPHROL 2003 23 5 465-476
40. 526561 The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, Sigal NH J EXP MED 1992 176 3 751-760
41. 526576 Cyclosporine- and FK-506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG CIRC RES 1993 73 3 596-602
42. 526578 Nephrotoxicity of cyclosporin A and FK-506: Inhibition of calcineurin phosphatase. Su Q, Weber L, Le HM, Zenke G, Ryffel B REN PHYSIOL BIOCHEM 1995 18 3 128-139
43. 526583 A randomized pilot study of cyclosporin G in renal transplantation. Ohlman S, Lindholm A, Gabel H, Wilczek H, Tyden G, Reinholt F, Sawe J, Groth CG TRANSPLANT INT 1992 5 Suppl 1 S464-S469
44. 526705 A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Peterson LB, Cryan JG, Rosa R, Martin MM, Wilusz MB, Sinclair PJ, Wong F, Parsons JN, O'Keefe SJ, Parsons WH, Wyvratt M et al TRANSPLANTATION 1998 65 1 10-18
45. 526709 Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Fruman DA, Klee CB, Bierer BE, Burakoff SJ PROC NATL ACAD SCI USA 1992 89 9 3686-3690
46. 526711 Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Batiuk TD, Pazderka F, Halloran PF TRANSPLANTATION 1995 59 10 1400-1404
47. 526713 The temporal profile of calcineurin inhibition by cyclosporine in vivo. Halloran PF, Helms L, Kung L, Noujaim J TRANSPLANTATION 1999 68 9 1356-1361
48. 526714 In vivo evaluation of the novel calcineurin inhibitor ISAtx247 in non-human primates. Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE J HEART LUNG TRANSPLANT 2003 22 12 1343-1352
49. 526718 ISAtx247: Phase I clinical trial results of the novel calcineurin inhibitor. Yatscoff RW, Abel MD, Aspeslet L, Freitag DG, Naicker SS, Trepanier DJ, Foster RT J RHEUMATOL 2001 28 63 Suppl Abs W109
50. 526725 Phase 2, randomized, multicenter, open-label study of ISA247 and Neoral in post-renal transplant patients. Yatscoff RW, Abel MD, Aspeslet LJ, Foster RT, Freitag DG, Huizinga RB, Mayo PR, Trepanier DJ AM J TRANSPLANT 2003 Abs 1215
51. 526729 Chronic cyclosporine-induced nephrotoxicity: A rabbit model. Thliveris JA, Yatscoff RW, Mihatsch MJ TRANSPLANTATION 1994 57 5 774-776
52. 526730 Psoriasis. Lebwohl M LANCET 2003 361 9364 1197-1204
53. 526731 Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Faerber L, Braeutigam M, Weidinger G, Mrowietz U, Christophers E, Schulze HJ, Mahrle G, Meffert H, Drechsler S AM J CLIN DERMATOL 2001 2 1 41-47
54. 526733 Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, Ke H PROC NATL ACAD SCI USA 2002 99 19 12037-12042
55. 526737 Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, Rich DH, Dunlap BE, Staruch MJ, Melino MR, Koprak SL J EXP MED 1991 173 3 619-628
56. 526740 Inhibition of T cell signaling by immunophilin ligand complexes correlates with loss of calcineurin phosphatase activity. Liu J, Schreiber SL BIOCHEMISTRY 1992 31 16 3896-3901
57. 526741 Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A. Ke H, Mayrose D, Belshaw PJ, Alberg DG, Schreiber SL, Chang ZY, Etzkorn FA, Ho S, Walsh CT STRUCTURE 1994 2 1 33-44
58. 526743 Distinct tissue and cellular distribution of two major isoforms of calcineurin. Jiang H, Xiong F, Kong S, Ogawa T, Kobayashi M, Liu JO MOL IMMUNOL 1997 34 8-9 663-669
59. 526745 Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N SCAND J IMMUNOL 2003 57 2 93-98
60. 526747 Substrate selectivity and sensitivity to inhibition by FK-506 and cyclosporin A of calcineurin heterodimers composed of the α or β catalytic subunit. Perrino BA, Wilson AJ, Ellison P, Clapp LH EUR J BIOCHEM 2002 269 14 3540-3548
61. 526748 Neoral-to-Gengraf conversion in renal transplant recipients. Carnahan W, Cooper TY TRANSPLANT PROC 2003 35 4 1308-1313
62. 526749 A new class of cyclosporin analogues for the treatment of asthma. Eckstein JW, Fung J EXPERT OPIN INVESTIG DRUGS 2003 12 4 647-653
63. 526750 New concepts in the treatment of rheumatoid arthritis. Goldbach-Mansky R, Lipsky PE ANNU REV MED 2003 54 197-216
64. 526762 Pharmacokinetics of a novel calcineurin inhibitor: ISAtx247. Yatscoff RW, Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Foster RT THER DRUG MONIT 2001 23 4 496
65. 526851 The state of the art in the management of inflammatory bowel disease. Hanauer SB, Present DH REV GASTROENTEROL DISORD 2003 3 2 81-92
66. 527989 ICTDMCT: PK-PD of ISA247 A Novel Calcineurin Inhibitor. Isotechnika Inc COMPANY PRESENTATION 2003 September 06
67. 529671 Cyclosporin clinical pharmacokinetics. Fahr A CLIN PHARMACOKIN 1993 24 6 472-495
68. 529679 DJ Analysts See Restructuring of Isotechnika/Roche Pact. Dow Jones Newswires PRESS RELEASE 2004 March 05
69. 529682 Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Kovarik JM, Burtin P EXPERT OPIN EMERG DRUGS 2004 8 1 47-62
70. 530371 Prolonged islet allograft survival without toxicity using ISAtx247, a novel calcineurin inhibitor. Shapiro AMJ, Rajotte RV, Lakey JRT, Bigam DL, Kneteman NM, Yatscoff RY MEET INT PANCREAS ISLET TRANSPLANT ASSOC 2001 TOPIC 3 Abs 03-29
71. 533789 Research comment: Isotechnica Inc. Flint P RBC CAPITAL MARKETS (US) 2004 March 29